Valore202020212022202320242025TTMSpese di vendita, generali e amministrative88.21 M102.8 M102.46 M76.16 M72.98 M73.54 M73.54 MRicerca e sviluppo266.95 M438.63 M461.64 M387.33 M320.65 M284.81 M284.81 MReddito operativo-354.44 M373.53 M-673.16 M-222.54 M-466.57 M-664.57 M-664.57 MProventi non operativi, Totale6.38 M6 M22.66 M71.82 M103.9 M86.61 M86.61 MOneri finanziari, al netto degli interessi capitalizzati———————Proventi non operativi, esclusi gli oneri finanziari0000000Entrate/uscite straordinarie6.38 M6 M22.66 M71.82 M103.9 M86.61 M86.61 MUtile al lordo delle imposte-348.06 M379.53 M-650.5 M-150.72 M-362.67 M-577.97 M-577.97 MQuota di utile-5.47 M-5.47 M—————Imposte809 K1.87 M-325 K2.89 M3.59 M3.63 M3.63 MInteressi di minoranza———————Altri proventi/oneri al netto delle imposte-1.86 M—-12.47 M16.55 M38.62 M23.53 M23.53 MUtile netto al lordo delle attività cessate-348.87 M377.66 M-650.17 M-153.61 M-366.25 M-581.6 M-581.6 MAttività cessate———————Utile netto-348.87 M377.66 M-650.17 M-153.61 M-366.25 M-581.6 M-581.6 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-348.87 M377.66 M-650.17 M-153.61 M-366.25 M-581.6 M-581.6 MUtile base per azione (EPS base)-5.294.97-8.36-1.94-4.34-6.47-6.47Utile diluito per azione (EPS diluito)-5.294.7-8.36-1.94-4.34-6.47-6.47Numero medio di azioni ordinarie in circolazione65.95 M75.95 M77.75 M79.22 M84.36 M89.93 M354.24 MAzioni diluite in circolazione65.95 M80.39 M77.75 M79.22 M84.36 M89.93 M354.24 MEBITDA-345.25 M391.48 M-648.99 M-202.7 M-447.31 M-645.09 M-645.09 MEBIT-354.44 M373.53 M-673.16 M-222.54 M-466.57 M-664.57 M-664.57 MCosto del fatturato———————Altri costi del venduto———————Ammortamento e svalutazione (liquidità)9.18 M17.95 M24.17 M19.84 M19.26 M19.48 M19.48 M
CRISPR Therapeutics AG
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.